Previous in vivo and in vitro studies revealed that esculetin (Fig.
1
) has anti-hepatitis B virus (anti-HBV) activity as well as a protective effect on liver damage caused by duck hepatitis B virus. We designed and synthesized a series of esculetin derivatives, introduced side chains containing various amino groups into site 7 of the parent structure, and synthesized C-4 and C-8 substituted derivatives with the goal of investigating their anti-HBV activities. In vitro anti-HBV activity was performed against HepG2.2.15 cells by using Enzyme-Linked Immunosorbent Assay(ELISA) kit and cytotoxicity was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay with lamivudine as the positive control. The results demonstrated that several compounds showed moderate anti-HBV activity, while the introduction of morpholine groups could significantly inhibit the expression of hepatitis B e antigen (HBeAg) and the introduction of the 2-methylimidazole group could significantly inhibit the expression of Hepatitis B surface antigen (HBsAg). Among all tested compounds, compound
4a
demonstrated the best anti-HBeAg activity (IC
50
= 15.8 ± 4.2 μM), while compound
6d
demonstrated the best anti-HBsAg activity (IC
50
= 21.4 ± 2.8 μM). Compounds
6b
and
6c
showed moderate anti-HBV activity and HBsAg inhibition. Compounds
4b
showed moderate anti-HBV activity and an inhibitory effect on HBeAg. In addition, compounds
4a
,
4c
,
4d
,
6b
,
6c and 6d
showed improved metabolic stability. This study provides useful guidance for the discovery of anti-HBV drugs, which merits further investigation.
Graphical Abstract